



## **pSivida Announces 13 New Patents Issued or Allowed**

### ***U.S. and foreign patents for bioerodible Medidur™, new smaller needle Medidur injector and Tethadur™***

Watertown, MA (August 29, 2016) – pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a leader in the development of sustained release drug delivery products primarily for eye diseases, announced the addition of 13 U.S. and foreign issued patents and allowed applications since the start of 2016. This brings the total number of patents issued and applications allowed in the Company's intellectual property portfolio to 42 in the U.S. and 191 in foreign jurisdictions. An additional 108 applications are pending in the U.S. and foreign jurisdictions.

Paul Ashton, Ph.D., president and CEO of pSivida, said, "Protection of our intellectual property continues to be extremely important to us. We have successfully secured intellectual property protection for our three FDA-approved products providing sustained drug delivery to the back of the eye and are working to build a solid patent foundation for future products."

The 13 new patents issued and applications allowed include:

- Two in the U.S. (both for Tethadur, pSivida's large-molecule sustained-release delivery technology)
- Eight in foreign jurisdictions (a total of five for Tethadur in Japan, China and Australia; one for the Medidur injector each in Japan and Hong Kong; and one for Medidur in Japan – Medidur is pSivida's small molecule sustained release delivery technology)
- Three design patents for the new smaller needle injector (two in Australia and one in Europe).

With these patents, pSivida's intellectual property portfolio of issued patents and allowed applications consists of:

- 10 U.S. and 82 foreign for Durasert;
- 27 U.S. and 88 foreign for Tethadur;
- 5 U.S. and 21 foreign for other pSivida technologies.

**About pSivida Corp.** pSivida Corp. ([www.psivida.com](http://www.psivida.com)), headquartered in Watertown, MA, is a leader in the development of sustained release, drug delivery products for treating eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN®, a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold in the U.S. and three EU countries. Retisert®, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSivida's lead product candidate, Medidur™, a micro-insert for posterior segment uveitis being independently developed, is currently in pivotal Phase 3 clinical trials, with an NDA anticipated in 2017. pSivida's pre-clinical development program is focused on using its core platform technologies Durasert™ and Tethadur™ to deliver drugs and biologics to treat wet and dry age-

related macular degeneration, glaucoma, osteoarthritis and other diseases. *To learn more about pSivida please visit [www.psivida.com](http://www.psivida.com) and connect on Twitter, LinkedIn, Facebook and Google+.*

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements include uncertainties with respect to: Designation of Medidur as an orphan medicinal product; our ability to achieve profitable operations and access to capital; fluctuations in our operating results; further impairment of our intangible assets; declines in Retisert royalties; successful commercialization of, and receipt of revenues from, ILUVIEN for DME; the effect of pricing and reimbursement decisions on sales of ILUVIEN for DME; consequences of fluocinolone acetonide side effects; safety and efficacy results of the second Medidur Phase 3 trial, number of trials and data required for, and timing of filing and acceptance of, the Medidur NDA and EU marketing approval applications, if at all; ability to use data in a U.S. NDA from trials outside the U.S.; any exercise by Pfizer of its option with respect to the latanoprost product; our ability to develop Tethadur to successfully deliver large biologic molecules and develop products using it; our ability to successfully develop product candidates, initiate and complete clinical trials and receive regulatory approvals; our ability to market and sell products; the success of current and future license agreements; termination or breach of current license agreements; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; legislative or regulatory changes; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the SEC. You should read and interpret any forward-looking statements in light of these risks. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements, even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.

Contact in US:

Beverly Jedynak

O: +1-312-943-1123

M: +1-773-350-5793

[blj@bevlynconsulting.com](mailto:blj@bevlynconsulting.com)

Contact in Australia:

Rudi Michelson

Monsoon Communications

O: 03 9620 333

M: 0411 402 737

[rudim@monsoon.com.au](mailto:rudim@monsoon.com.au)